Thank morning, you, good Kristin, and everyone.
Kristin had strong and As broad-based both across third segments our portfolios quarter, and animal across growth a U.S. lifestyle both and and companion mentioned, International with both volume. we across price
our In basis. For $X.X on revenue able and we growing headwinds China. a generated to with third were billion, line continued we basis results the quarter, deliver of in X% an light in even quarter, of operational reported in the on X% expectations,
an Of the million X% monoclonal portfolio. a basis. pain, from X% for on $XXX growth from of XX% XX% and revenue price products, X% growth, reported from dermatology our antibodies Volume operational and income Librela net of Adjusted grew from on X% our including X% is new consisted OA Solensia is basis and key and operational volume.
portfolio operationally. driver growing growth growth, XX% of in also X% Our of the companion main with revenue contributed, animal Livestock operational was the quarter.
driven products animal by our antibodies our in our innovative Companion growth double-digit key Librela and monoclonal portfolio, again operational growth Simparica for dermatology with and pain, Trio. was Solensia OA
International. an growth growth in in $XXX sales both U.S. products and dermatology on XX% of posting generated basis double-digit operational key million with globally, the Our
the quarter. combined from our revenue internationally. markets the impact Globally, new came pain primarily Growth million for as markets monoclonal $XX of European as in antibodies in our from launch OA posted well
Growth from OA products markets. versus driven full revenue now $XXX most by in was October U.S., Simparica of launch the in Librela period. in Trio promotional and the pain are of increased available comparable of our XXXX as million support quarter, representing globally the operationally well focus. posted force DTC With advertising growth major global as expanded field the XX%
Our International. diagnostics both contributions grew and million U.S. and animal operationally, portfolio $XX with of companion growth the reported revenue from XX%
grew International decline operationally, U.S. by a growth portfolio X% Lifestyle with Our offset in the partially slight
livestock Growth in primarily inflationary driven high markets. in price, especially by was
poultry our We well vaccines Zoamix also saw usage antioxodio in our increased U.S. of by as as volume portfolio, product, driven growth ] [ the in
the declining Now with X%. growing in on growing billion revenue the $X.X products XX% animal growth and segment was U.S. moving revenue for quarter. sales livestock quarter, to X%, companion by
basis, while year animal X%. Average per in visits to visit quarter, continue play On over flat, growth, companion year-to-date is the up is impact as revenue in declined revenue the challenges. These durability continued clinic clinic the ago. vet continued On of the see visits highlight growing while as pet up staffing trends well revenue clinic robust a versus vet X%. side, X.X% we a clinic to X% spend are of willingness owner
part veterinary revenue clinic growth companion in in due growth our growth, animal retail Our continued to channel. upsized to continues outpace revenue
and to duration product million growth in drive for U.S. Cytopoint quarter, the Companion vets was Simparica Turning in owners sales pet continued a dermatology in by longer product Trio driven and appreciating due Key the quarter growing Solensia. U.S. to key portfolio, compliance $XXX the were preference our performance. the treatment. growth injectables in showing to dermatology XX%. sales the with higher of animal
Apoquel were driven pet ongoing drive retail that needs pharmacy as channel auto more the to ship continue owners as growth higher retail well for by sales programs as in heavily on rely compliance. retail
Europe, has life Our well cycle in in over tablets. chewable of as launched received the pet favor U.S. latest October. Apoquel in administration owners dermatology ease Apoquel the film-coated been Chewable innovation, Chewable was
our Chewable in growing focus XX%, programs. driven sales the parasiticide by million quarter, posted in U.S. of $XXX increased Apoquel promotional
launch in the growth in with superior presence, the even in strong our combination remain space. Simparica channel to retail competitive continue confident relationships. We label, share triple compete and strength patient of ability corporate recent Trio, specialty our the see through our to We and
of the In sales the $XX quarter. pain products in our posted million U.S., OA
DTC OA We expect of to an growth continue penetration campaigns. feline uptick and to to our advertising feline Solensia, clinic see well awareness in through drive solid continue as player as for visits
Librela third has and mid-October. to in participants We patients been the moved quarter. program by early their a during full experience launch well received
launch far very post that been performance pleased supply meet have ample to and our demand we confident with are have We expectations. thus
posted in on we quarter, placement portfolio field images device. positive introduced last diagnostics year. especially animal XX% in growth the companion growth saw as force U.S. from we Our quarter, our strong to new see the results We continue the of
decline U.S. claims. sales growth supply on improved year, QX X% had partially SYNOVEX position the the productivity quarter. we quarter, to declined timing by in an in and strong label of products in implant, supply from resulting livestock due channel, where comparable was our the cattle a restocking offset the The drove extended in primarily cattle which prior certain
vaccines cattle Zoamix, offset poultry growth decline and antibiotic to in partially to use of additives. feed by extended medicated the The alternative due was an
OA for our companion Increased operationally. dermatology X% reported revenue sales our small and growth monoclonal where grew from grew operational our to pain, International products segment, in revenue livestock animal companion basis International of on on in parasiticides animal portfolio. resulted our grew the antibodies and XX% Moving and X% key quarter. products both operationally animal
in Growth markets, field bolstered launched well awareness as our early OA and earlier U.K. and in products in force specifically the focus European was Germany, by markets year. the pain uptake as this continued campaigns launch DTC
quarter, International the in comparator our International due our Librela markets. removal more QX in We XX% sales ability to constraints Librela. the despite supply growth were million for supply demand a to slightly our confident in or XXXX $XX operational of difficult of forecasted in remain
$XX sales quarter. were million in Solensia the
and itch and key our Chewable. driven delayed We and saw growth of Apoquel grew most higher uptake season strong Cytopoint expansion driven portfolio existing patient revenue in operationally. Apoquel of growth dermatology Our contributed in million continued of across was by XX% International by Europe patients. growth $XXX markets was and compliance primarily the Canada. major double-digit
in Our contracts. primarily X% growing growing on was with Trio International franchise, XX% revenue, an Simparica our emerging posting small posted operationally driven million, driven $XX markets. of account XX% by by animal basis, growth driven parasiticides Simparica portfolio $XX demand in growth generation million operational operationally, in by Simparica corporate
well in performance Simparica in offset prior comparable return of in The as by ongoing China, operational was of difficult a by decline Revolution the the as current year partially the due conditions. XX% supply period driven economic impact a the franchise, franchise to
in ongoing were animal fully declines economic seen side, guidance. have to challenges, we particularly which China mentioned, due companion on our in the the Kristin As initial reflected not
We to monitor economic continue conditions.
first the However, are year. into of not improvement or next we expecting an year this half
we inflationary on X% International in recovery largest our quarter, portfolio, increases, cattle segment price price driven high livestock where certain growth, Brazil improvement by have was the Our X% operationally. Growth was grew industry products grew especially which in by primarily cattle well dynamics. primarily seen driven the contributor, continued as as markets. in operationally supply
uncertain industry inventories quarter. impact the a disruptions in due a and to Additionally, to led channel the weak lowering dynamic prior comparative year of of period was the more supply a
operationally account in to due penetration Our growing emerging to poultry markets. key X% growth in the increased contributed quarter, also business
moving reported Adjusted improved offset prior and of quarter. and to rest lower primarily points XX.X% Now basis for basis inventory charges. manufacturing increases margin mix. the on the freight partially XX impact the compared the driven of by the to product gross higher P&L year, costs, of by on a charges This was price
increased X% pipeline higher SG&A the higher as well competition projects. project due expenses, basis expenses increased primarily which on expenses our X% XX% grew as were higher operating for Adjusted operational by compensation-related R&D operationally, to related driven by in expenses. expenses an quarter, driven operationally spend
to by a and related offset of intangible benefit The basis for net adjusted mix effective tax foreign-derived tax a income, points the decrease rate in discrete XXX to lower quarter jurisdictional U.S. favorable earnings was due partially of higher XX.X%, the benefits.
XX% adjusted Zoetis the quarter net In now diluted shares. in year the $XXX expenditures grew operationally million. we was of to capital operationally finally, million to quarter, million We $XXX the EPS for million. repurchased and $XXX quarter. were of range be adjusted $XXX the income in And expect expenditures Capital XX% third full
Now note of foreign October, for as XXXX. moving which the strengthening the the dollar. rates Please to continued U.S. guidance guidance late full year of that reflect exchange reflects
growth. rates, unfavorable while with reported Beginning operational the for our year. revenue are foreign range our Due revising guidance full on to exchange revenue narrowing revenue we
X.X% billion, to expect $X.XXX growth. operational with of range billion We and $X.XX X.X% revenue a between
Our was to X% previous guidance X%.
pleased have performance operational our We been far. with thus
been revenue growth line larger in foreign expected, have X% headwinds of expectations. our than year-to-date While exchange our operational is with
the Librela is our We included expect which to business. performance guidance last the quarter of in launch Lifestyle well in benefit from the our of as approval and as U.S., revised
continued has China offset in uncertainty potential. ongoing upside However, to
of we diluted to X.X%, of the range of range diluted narrows to growth expecting X%. unfavorable our $X.XX exchange. billion reported adjusted expectations to $X.XX. to to foreign net also X.X% $X.XX to $X.XX. are are a be in a X% We $X.XX income to billion, previously Expected Operationally, slightly by range to narrows EPS And driven to adjusted EPS lower, $X.XX narrowing
go to Finally, to summarize we Q&A. before
industry. and and by remain Our broad-based and multiple across in-line the to despite the animal of portfolio, environment in highlight to above species the China, our committed growth economic challenging geographies sources growth. continue the of innovative health portfolio resilience execution driven of our We growing commercial industry,
line to hand Now your I'll things over the operator to questions. the for open Operator?
